Bionik Laboratories (BNKL) stock price, revenue, and financials

Bionik Laboratories market cap is $10 m, and annual revenue was $1.19 m in FY 2021

$10 M

BNKL Mkt cap, 10-Nov-2021

$1.2 M

Bionik Laboratories Revenue FY, 2021
Bionik Laboratories Gross profit (FY, 2021)923.8 K
Bionik Laboratories Gross profit margin (FY, 2021), %77.4%
Bionik Laboratories Net income (FY, 2021)-13.6 M
Bionik Laboratories EBIT (FY, 2021)-13.3 M
Bionik Laboratories Cash, 31-Mar-2021600 K
Bionik Laboratories EV12.7 M
Get notified regarding key financial metrics and revenue changes at Bionik LaboratoriesLearn more
Banner background

Bionik Laboratories Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Revenue

7.5k5.2k6.0k571.9k987.4k1.2m

Cost of goods sold

7.0k388.8k402.7k1.6m893.4k269.6k

Gross profit

(1.0k)183.2k584.8k923.8k

Gross profit Margin, %

(17%)32%59%77%

Sales and marketing expense

1.2m2.0m2.3m2.2m1.0m

R&D expense

1.5m343.7k2.7m2.8m3.2m3.9m1.5m

General and administrative expense

11.5k16.5k18.3k28.5k2.7m1.4m3.3m3.6m3.9m4.2m3.8m

Operating expense total

11.5k16.5k18.3k28.5k4.2m1.8m7.2m8.4m9.4m10.3m14.3m

Depreciation and amortization

59.5k14.4k629.9k412.9k348.2k380.6k

EBIT

(4.5k)(13.1k)(29.5k)(13.3m)

EBIT margin, %

(252%)(492%)(1118%)

Interest expense

182.0381.03.0k43.7k1.3m405.3k

Pre tax profit

(4.7k)(5.6m)(1.0m)(3.9m)(14.6m)(10.6m)(25.0m)(13.6m)

Income tax expense

Net Income

(4.7k)(9.4k)(13.1k)(29.5k)(5.6m)(1.0m)(3.9m)(14.6m)(10.6m)(13.6m)

Bionik Laboratories Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Cash

12.5k4.9k4.4k3.2k6.6m5.4m543.7k507.3k446.8k2.3m600.0k

Accounts Receivable

125.2k212.7k1.5m847.0k451.9k

Prepaid Expenses

188.2k231.7k433.7k1.4m1.6m1.7m

Inventories

228.2k237.4k405.7k1.1m692.2k

Current Assets

12.5k4.9k4.4k3.2k7.2m6.2m1.4m1.4m3.7m5.8m3.4m

PP&E

87.1k76.8k160.0k192.5k154.1k93.6k

Goodwill

22.3m22.3m22.3m11.1m4.3m

Total Assets

12.5k4.9k4.4k3.2k7.2m6.2m29.0m28.6m30.7m18.5m8.8m

Accounts Payable

150.016.5k134.7k320.9k784.7k724.7k1.1m857.1k454.8k

Short-term debt

51.5k2.1m2.2m

Current Liabilities

6.3k1.7k14.2k42.6k5.8m8.1m3.3m5.2m4.1m

Long-term debt

1.1m

Total Debt

51.5k2.1m3.3m

Total Liabilities

6.3k1.7k42.6k6.3m6.0m5.5m

Common Stock

5.0k116.2k96.6k72.4k72.6k249.6k3.9k5.1k5.7k

Preferred Stock

Additional Paid-in Capital

13.7k20.1k(91.0k)(71.4k)11.4m11.8m38.6m55.9m73.7m84.6m88.2m

Retained Earnings

(64.6k)(10.6m)(11.7m)(35.8m)(46.4m)(71.4m)(85.0m)

Total Equity

6.1k3.3k(9.8k)(39.3k)978.0k263.9k23.2m20.5m27.4m13.3m3.3m

Debt to Equity Ratio

0.2 x

Debt to Assets Ratio

0.1 x

Financial Leverage

2 x1.5 x-0.5 x-0.1 x7.4 x23.6 x1.2 x1.4 x1.1 x1.4 x2.7 x

Quarterly

USDQ3, 2011Q1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

8.0k10.6k15.6k567.01.5k3.0k5.9k7.3k8.8k6.1m9.1m7.9m2.7m1.7m581.0k846.4k136.1k998.7k959.7k305.8k375.1k

Accounts Receivable

79.0120.4k93.9k253.8k134.9k37.2k306.6k370.2k517.8k1.5m

Prepaid Expenses

158.4k164.4k128.0k188.4k157.1k153.0k172.1k169.3k145.0k485.4k851.2k1.8m

Inventories

260.3k294.0k194.6k255.5k231.4k302.4k155.8k192.6k335.6k

Current Assets

8.1k10.6k15.6k1.5k3.0k5.9k7.3k8.8k6.3m9.4m8.3m3.4m2.3m1.2m1.4m593.4k1.8m2.0m1.9m4.1m

PP&E

100.6k114.5k98.4k126.3k196.0k203.7k218.5k196.2k175.0k150.2k139.4k135.8k

Goodwill

27.9m27.9m27.9m22.3m22.3m22.3m22.3m22.3m22.3m

Total Assets

8.1k10.6k15.6k567.01.5k3.0k5.9k7.3k8.8k6.4m9.5m8.4m31.4m30.3m29.3m28.9m28.0m29.0m29.1m28.9m31.0m

Accounts Payable

150.02.4k3.6k208.8k197.1k130.7k377.0k419.9k405.3k890.6k957.4k794.9k736.1k906.4k1.4m

Short-term debt

6.0k4.6k4.6k4.6k332.9k335.3k50.0k

Current Liabilities

6.1k6.4k6.3k150.06.9k10.1k16.6k21.6k24.5k7.1m5.0m4.7m6.4m7.1m10.3m5.1m2.0m6.3m

Long-term debt

6.0k18.0k16.9k15.7k

Total Debt

6.0k6.0k22.6k226.7k231.8k332.9k192.2k50.0k

Total Liabilities

6.1k6.4k24.5k8.9m12.3m249.6k7.4m5.4m5.0m

Common Stock

4.9k5.0k5.0k5.1k116.2k116.2k116.2k116.2k116.2k65.8k72.4k72.4k85.1k96.4k96.4k101.8k101.8k101.8k289.1k2.6k2.6k

Preferred Stock

Additional Paid-in Capital

4.9k13.7k13.7k20.1k(91.0k)(91.0k)(91.0k)(91.0k)(91.0k)10.1m11.4m18.0m26.7m38.1m38.2m40.2m47.6m48.1m60.1m67.4m67.6m

Retained Earnings

(12.7m)(14.2m)(9.9m)(14.0m)(13.2m)(14.1m)(17.8m)(27.0m)(29.6m)(36.5m)(40.5m)(42.9m)

Total Equity

2.0k4.2k9.0k417.0(5.4k)(7.2k)(10.7k)(14.3k)(15.7k)(2.5m)(2.7m)8.2m24.0m25.0m24.3m22.5m20.9m18.7m23.9m26.9m24.7m

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

4 x2.5 x1.7 x1.4 x-0.3 x-0.4 x-0.5 x-0.5 x-0.6 x-2.6 x-3.5 x1 x1.3 x1.2 x1.2 x1.3 x1.3 x1.6 x1.2 x1.1 x1.3 x

Bionik Laboratories Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(4.7k)(9.4k)(13.1k)(29.5k)(5.6m)(1.0m)(3.9m)(14.6m)10.6m(13.6m)

Depreciation and Amortization

59.5k14.4k629.9k412.9k348.2k380.6k189.7k

Accounts Receivable

(377.4k)190.9k(1.3m)508.7k395.1k

Inventories

(39.4k)(9.2k)(168.2k)(653.8k)332.5k

Accounts Payable

(1.5k)16.3k(174.2k)186.2k(332.0k)(60.1k)424.2k(291.8k)(407.9k)

Cash From Operating Activities

(4.2k)(8.1k)(14.6k)(13.2k)(4.6m)(1.0m)(7.0m)(7.7m)(9.2m)(9.1m)(4.6m)

Purchases of PP&E

Cash From Investing Activities

(380.2k)(196.9k)(170.8k)(21.6k)(101.8k)(159.6k)

Short-term Borrowings

(600.0k)(523.8k)

Cash From Financing Activities

8.9k14.1k12.0k11.3m2.3m7.7m9.3m11.0m3.0m

Net Change in Cash

4.6k14.6k(13.2k)6.4m(1.2m)(4.8m)(36.3k)(60.5k)1.8m(1.7m)

Interest Paid

Income Taxes Paid

Bionik Laboratories Ratios

USDQ3, 2011

Financial Leverage

4 x

Bionik Laboratories Employee Rating

1.65 votes
Culture & Values
1.3
Work/Life Balance
2.4
Senior Management
1
Salary & Benefits
2
Career Opportunities
1
Source